These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28864920)

  • 1. Discovery of mutations in homologous recombination genes in African-American women with breast cancer.
    Ding YC; Adamson AW; Steele L; Bailis AM; John EM; Tomlinson G; Neuhausen SL
    Fam Cancer; 2018 Apr; 17(2):187-195. PubMed ID: 28864920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel germline PALB2 truncating mutations in African American breast cancer patients.
    Zheng Y; Zhang J; Niu Q; Huo D; Olopade OI
    Cancer; 2012 Mar; 118(5):1362-70. PubMed ID: 21932393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutations in PALB2 in African-American breast cancer cases.
    Ding YC; Steele L; Chu LH; Kelley K; Davis H; John EM; Tomlinson GE; Neuhausen SL
    Breast Cancer Res Treat; 2011 Feb; 126(1):227-30. PubMed ID: 21113654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
    Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S
    Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
    Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
    Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
    Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P
    Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and spectrum of mutations across 94 cancer predisposition genes in African American women with invasive breast cancer.
    Lovejoy LA; Rummel SK; Turner CE; Shriver CD; Ellsworth RE
    Fam Cancer; 2021 Jul; 20(3):181-187. PubMed ID: 33083949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
    Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
    Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
    Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
    Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of protein-truncating and missense variants in
    Ng PS; Boonen RA; Wijaya E; Chong CE; Sharma M; Knaup S; Mariapun S; Ho WK; Lim J; Yoon SY; Mohd Taib NA; See MH; Li J; Lim SH; Tan EY; Tan BK; Tan SM; Tan VK; van Dam RM; Rahmat K; Yip CH; Carvalho S; Luccarini C; Baynes C; Dunning AM; Antoniou A; van Attikum H; Easton DF; Hartman M; Teo SH
    J Med Genet; 2022 May; 59(5):481-491. PubMed ID: 33811135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.
    Rodrigue A; Margaillan G; Torres Gomes T; Coulombe Y; Montalban G; da Costa E Silva Carvalho S; Milano L; Ducy M; De-Gregoriis G; Dellaire G; Araújo da Silva W; Monteiro AN; Carvalho MA; Simard J; Masson JY
    Nucleic Acids Res; 2019 Nov; 47(20):10662-10677. PubMed ID: 31586400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Alter BP; Best AF
    Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
    Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
    Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Missense PALB2 germline variant disrupts nuclear localization of PALB2 in a patient with breast cancer.
    Toh MR; Low CE; Chong ST; Chan SH; Ishak NDB; Courtney E; Kolinjivadi AM; Rodrigue A; Masson JY; Ngeow J
    Fam Cancer; 2020 Apr; 19(2):123-131. PubMed ID: 32048105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
    Beebe-Dimmer JL; Zuhlke KA; Johnson AM; Liesman D; Cooney KA
    Prostate; 2018 Apr; 78(5):321-326. PubMed ID: 29356034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.